No retraction, correction or concern found when last checked on Oct 26, 2026.
The PI3K/Akt pathway: a critical player in intervertebral disc degeneration
Zhi-Hua Ouyang, Wen-Jun Wang, Yi-Guo Yan and 2 more
Oncotarget · 2017 · Review
Abstract
Intervertebral disc degeneration (IDD) is thought to be the primary cause of low back pain, a severe public health problem worldwide. Current therapy for IDD aims to alleviate the symptoms and does not target the underlying pathological alternations within the disc. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway protects against IDD, which is attributed to increase of ECM content, prevention of cell apoptosis, facilitation of cell proliferation, induction or prevention of cell autophagy, alleviation of oxidative damage, and adaptation of hypoxic microenvironment. In the current review, we summarize recent progression on activation and negative regulation of the PI3K/Akt signaling pathway, and highlight its impact on IDD. Targeting this pathway could become an attractive therapeutic strategy for IDD in the near future.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.
INTRODUCTION
Low back pain (LBP) is a major public health problem worldwide, resulting in a huge socioeconomic burden. Although the etiology of LBP is complex, intervertebral disc degeneration (IDD) has been regarded as the primary cause. It is acknowledged that genetic predisposition, aging and lifestyles including occupational exposure, smoking, and alcohol consumption are implicated in disc degeneration. Although its pathogenesis is not fully elucidated, loss of active IVD cells, progressive breakdown of extracellular matrix (ECM), alternation of intervertebral disc (IVD) cell phenotypes, and excessive inflammatory response have been proposed as critical contributors to IDD. Current therapy for IDD aims to relieve pain and control symptom rather than interfere with its pathophysiology. Although several biological strategies capable of slowing mild and moderate disc degeneration through induction of ECM remodeling have been considered, their clinical efficacy remains to be determined. Therefore, a better understanding of its pathogenesis is essential to develop effective treatments.
The intervertebral disc (IVD) is made up of the central nucleus pulposus (NP), the peripheral annulus fibrosus (AF) enclosing NP, and the upper and lower cartilaginous endplates (CEPs). These three distinct anatomic regions form a complicated structure for maintaining spinal stability. The IVD is the biggest avascular tissue in human body, with limited blood supply via peripheral capillaries. Given the fact that the IVD resides in a nutrient deficient environment, disc degeneration is prone to occur if nutrition is depleted or impeded.
Dysregulation of multiple signaling pathways has been shown to be implicated in disc degeneration. As a main intracellular signaling pathways, activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway can modulate cell proliferation, apoptosis, autophagy and differentiation under the physiological and pathological conditions by interacting with multiple downstream target proteins, including mammalian target of rapamycin (mTOR) and forkhead box O1 (FoxO1). More importantly, targeting this pathway has shown promise for the prevention or reversal of IDD. In this review, after introduction of the PI3K/Akt pathway, we explore its role in disc degeneration.
Activation of the PI3K/Akt signaling pathway and downstream effectors
As a unique family of intracellular lipid kinases, PI3Ks contain three classes (Class I, II and III). Among these, Class I is the most studied, which is subdivided into class IA (PI3Kα, β and δ) and class IB (PI3Kγ). Class I PI3Ks are heterodimer that are made up of a catalytic subunit (p110α, β, γ or δ,) and a regulatory subunit (p85α, β or γ). Akt, a serine/threonine kinase, includes three isoforms (Akt1, 2, and 3). These isoforms have high homology.
Class IA and class IB PI3Ks are activated by different agents. Receptor tyrosine kinases (RTKs) are transmembrane glycoproteins with enzymatic activity. PI3Kα, PI3Kβ and PI3Kδ are activated when an extracellular ligand binds to a RTK. In contrast, both G-protein-coupled receptors (GPCRs) and small GTPase Ras are responsible for PI3Kγ activation. Once activated, PI3Ks convert membrane-bound phosphatidylinositol 4,5-biphosphate (PIP2) into phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 then recruits phosphoinositide- dependent kinase 1 (PDK1) to phosphorylate Akt at threonine 308 (Thr308). Subsequently, mTOR complex 2 (mTORC2) phosphorylates Akt at serine 473 (Ser473) for full AKT activation. Thereafter, activated Akt interacts with downstream target proteins to regulate multiple biological processes, including apoptosis, autophagy and cell cycle progression (Figure 1).
As an evolutionarily conserved serine/threonine protein kinase from yeast to mankind, mTOR interacts with other proteins to form two multiprotein complexes: mTORC1 and mTORC2. The mTORC1 is extremely sensitive to rapamycin, whereas mTORC2 is insensitive to rapamycin. The activated Akt reduces the formation of tuberous sclerosis complex (TSC) 1/2 and then inhibits the conversion of GTP-Rheb to GDP-Rheb. Increased GTP-Rheb activates mTORC1. Subsequently, mTORC1 induces the phosphorylation of ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). Once phosphorylated, the latter stimulates the release of eukaryotic translation initiation factor 4E (eIF4E). Both S6K and eIF4E finally promote protein translation and cell proliferation.
Besides mTORC1, Akt is capable of deactivating both glycogen synthase kinase 3β (GSK3β) and FoxO1 by stimulating their phosphorylation. Inactivation of GSK3β increases the biogenesis of cyclin D1 and then accelerates cell cycle. FoxO1 contains a conserved forkhead domain and three putative phosphorylation sites for Akt. Decreased activity of FoxO1 restrains the transcription of p27 and p21, two inhibitors of cyclin-dependent kinase (CDK), resulting in cell cycle progression. Activated PI3K/Akt signaling can also facilitate cell survival via attenuating pro-apoptotic Bad, Bax and p53 levels as well as enhancing anti-apoptotic Bcl-2 and Bcl-xl levels.
Negative regulators
The major negative regulator of this pathway is phosphatase and tensin homolog (PTEN) that converts PIP3 back to PIP2, an opposite action with PI3K (Figure 1). Notably, the activated PI3K/Akt pathway can also facilitate ubiquitin-mediated proteasomal cleavage of PTEN by upregulating the expression of NEDD4-1 (an E3 ligase), leading to permanent activation of this pathway in a positive feedback loop. In addition to PTEN, there are some specific inhibitors targeting PI3K or Akt. The PI3K inhibitors primarily contain LY294002, BYL719 and BKM120. The Akt inhibitors consist of MK-2206, GSK690693 and RX0201.
ROLES OF THE PI3K/AKT PATHWAY IN THE PATHOGENESIS OF IDD
IDD is a complicated disease involving numerous pathologic processes. As expected, the PI3K/Akt pathway takes part in disc degeneration through multiple mechanisms (Figure 2), which will be discussed in detail below.
Increase of ECM content
The hallmark of IDD is progressive loss of ECM components due to increased production of matrix metalloproteinases (MMPs) and a disintegrin and metalloprotease with thrombospondin motifs (ADAMTSs). Insulin-like growth factor-1 (IGF-1) has a significant protective effect against IDD. Serum (IGF-1) levels were lower in lumbar disc degeneration patients than those of healthy controls, and addition of IGF-1 to human NP SV40 cells induced Akt phosphorylation and then inactivated FoxO1, leading to inhibition of MMP-3 transcription. In rat endplate chondrocytes, addition of IGF-1 dramatically decreased the expression and activity of MMP-13 by activating the PI3K/Akt pathway, which increased type II collagen (Col II) content. Additionally, treatment of bovine NP cells with IGF-1 combined bone morphogenetic protein 7 (BMP-7) synergistically promoted aggrecan accumulation by enhancing Akt activity. Accumulating evidence suggests that dysregulation of microRNAs (miRNAs) participates in disc degeneration. Recently, Liu and colleagues observed that miR-4458 levels were significantly increased in degenerative human lumbar disc specimens. They also found that transfection of human NP cells with miR-4458 mimic inhibited the PI3K/Akt signaling via silencing of insulin-like growth factor 1 receptor (IGF-1R), leading to increased ECM breakdown. Collectively, activated PI3K/Akt pathway contributes to prevention of disc ECM degradation.
In addition to blockade of ECM catabolism, activation of this pathway promotes its anabolism. Sox9 is an important transcriptional factor that can drive aggrecan gene expression. It has been reported that miR-30a attenuates aggrecan content by targeting Sox9 in primary chondrocytes from cartilage isolated from osteoarthritis donors. In contrast, overexpression of Sox9 dramatically facilitated aggrecan production in cultured human articular chondrocytes. Similarly, activation of the PI3K/AKT signaling increased Sox9 expression and activity, which subsequently induced transcription of aggrecan gene in rat NP cells.
Inhibition of cell apoptosis
In general, apoptosis occurs via two well-characterized pathways in mammalian cells: the death receptor or extrinsic pathway and mitochondria or intrinsic pathway. IVD cell loss resulting from excessive apoptosis has long been considered to be an important cause of reduced ECM synthesis during disc degeneration. In addition to modulation of intradiscal ECM metabolism, this pathway can suppress apoptosis of IVD cells. Administration of 17β-estradiol combined with resveratrol (a natural polyphenol compound) promoted Akt phosphorylation and decreased caspase-3 activity, leading to apoptosis inhibition in rat NP cells treated with interleukin-1β (IL-1β). Transforming growth factor-β1 (TGF-β1) is a key factor during the development of both cartilage and spine tissues. Mesenchymal stem cell transplantation with pure fibrinous gelatin-TGF-β1 markedly decreased degenerative degree in a rabbit IDD model. Treatment of rat AF cells with TGF-β1 was found to reduce apoptosis incidence by activating the PI3K/AKT/mTOR pathway under serum deprivation. Conversely, miR-27a overexpression induced apoptosis of human degenerated NP cells via silencing of PI3K. Thus, in vivo delivery of miR-27a inhibitors might be a promising therapeutic strategy to restore the number of viable NP cells for IDD patients.
Sirtuin 1 (SIRT1) is a NAD+-dependent class III histone deacetylase. The protective effects of SIRT1 against disc degeneration are primarily derived from its abilities to promote ECM anabolism, inhibit inflammatory response and alleviate senescence of CEP cells. It has been demonstrated that SIRT1 markedly decreases the rate of apoptosis in multiple cell types, such as osteoblast-like MC3T3-E1 cells, human kidney proximal tubule epithelial cells, cardiomyocytes, and chondrocytes. In human degenerative NP cells, SIRT1 was also reported to protect against apoptosis via autophagic induction. Notably, resveratrol-induced SIRT1 activation stimulated Akt phosphorylation and reduced apoptotic incidence of human NP cells, whereas either Akt knockdown or LY294002 abrogated the inhibitory effect of SIRT1 on NP cell apoptosis. In a later study, miR-138-5p knockdown upregulated the expression of its target gene SIRT1 and then inhibited apoptosis in human NP cells treated by tumor necrosis factor-α (TNF-α). Mechanistically, upregulation of SIRT1 decreased PTEN levels to activate the PI3K/Akt pathway. These findings reveal the PI3K/AKT signaling as another important mechanism for SIRT1-mediated inhibition of NP cell apoptosis. Targeting this pathway might have enormous potential for retarding or reversing disc degeneration.
Promotion of cell proliferation
Appropriate proliferation of IVD cells represents a tissue repair process during disc degeneration. In addition to blockade of IVD cell apoptosis, this pathway can raise the number of viable IVD cells by promoting cell proliferation. In human IVD cells, exogenous treatment with either PDGF or IGF-1 stimulated DNA synthesis, which was at least partially attributed to activation of this pathway. A similar effect was also observed in bovine coccygeal NP and AF cells. Conversely, high osmolality significantly reduced Akt phosphorylation and then inhibited PDGF or IGF-I-induced synthesis of novel DNA in bovine NP cells. Leptin belongs to a peptide hormone, and its plasma levels are significantly increased in obesity patients. It can be produced by fibrocartilaginous tissues, such as articular cartilage and IVD, besides adipose tissues. Recently, Zhao et al. reported that human herniated disc tissues expressed leptin and its functional receptor, and administration of leptin could stimulate rat NP cell proliferation. Leptin also promoted the proliferation of primary cultured human NP cells. Mechanistically, leptin increased cyclin D1 expression via inhibition of Akt phosphorylation. Thus, the PI3K/AKT signaling may function as a cross-talk between obesity and IDD.
MiR-21 functions as an inducer of cell proliferation. Interestingly, transfection of human NP cells with miR-21 mimic dramatically increased Akt activity via targeting PTEN, leading to upregulation of cyclin D1 expression and subsequent cell proliferation. It is worth noting that overexpression of miR-21 could also stimulate these cell proliferation via silencing of programmed cell death 4 (PDCD4). Recently, Li et al. identified growth arrest specific gene 1 (GAS1) as a direct and functional target of miR-184. Moreover, ectopic expression of miR-184 markedly attenuated GAS1 levels, which promoted Akt phosphorylation and human NP cell proliferation. Like miR-21 and miR-184, miR-10b is also a multi-functional miRNA. Aberrant expression of this miRNA contributed to the proliferation of malignant tumor cells. Similar to these reports, transfection of human NP cells downregulated homeobox D10 (HOXD10) expression, leading to increased Akt phosphorylation and cell proliferation. However, restored expression of HOXD10 or Akt suppression reversed the mitogenic effect of miR-10b. Taken together, miR-21, miR-184 and miR-10b promote NP cell proliferation by activating the PI3K/AKT signaling.
Regulation of cell autophagy
Autophagy is an orchestrated homeostatic process involving the degradation and digestion of intracellular components by lysosomes. Recent studies have focused on the relationship between autophagy and IDD. There is a low basal level of autophagy in normal NP and AF cells. In contrast, degenerative NP and AF cells exhibited a significant increase in the autophagic activity. When compared with healthy controls, human degenerated AF tissues showed more autophagic vacuolization and autophagosomes. In NP cells isolated from rat lumbar discs, hydrogen peroxide (H2O2) induced an early autophagic response via the extracellular signal-regulated kinase (ERK)/mTOR pathway; however, prevention of autophagy by 3-methyladenine (3-MA) markedly attenuated the apoptosis of H2O2-treated NP cells. On the other hand, human degenerative NP cells exhibited a marked decrease in autophagy activity. Importantly, activation of autophagy by rapamycin suppressed IL-1β-induced ECM degradation in rat NP cells. Thus, autophagy acts as a double-edged sword in the development of IDD, depending on the stimuli.
The PI3K/Akt pathway is closely associated with autophagy. Recently, Ni et reported that treatment of rat AF cells with TGF-β1 markedly decreased autophagy incidence by activating the PI3K/AKT/mTOR signaling pathway under serum deprivation, leading to increased viable cell number. Notably, IGF1 promoted the survival of human NP cells exposed to compression via autophagy induction, which was abrogated by the specific Akt inhibitor LY294002. These findings reveal a complex role of this pathway in regulating IVD cell autophagy. This discrepancy may be attributed to the differences in stimuli, cell types and downstream effectors. However, both alterations of autophagy activity contribute to its protection against IDD (Figure 3).
Alleviation of oxidative damage
Oxidative stress is a critical contributor to disc degeneration, because it not only reinforces ECM degradation and inflammatory response, but also reduces the viability and number of IVD cells. Once activated, the PI3K/Akt pathway can enhance endogenous antioxidant ability in multiple cell types, such as macrophages, human umbilical vascular endothelial cells, and intestinal epithelial cells. Epigallocatechin 3-gallate (EGCG) is known to delay painful disc degeneration by reducing inflammation and catabolism. Recently, Krupkova et al. reported that EGCG administration protected human degenerative NP cells from oxidative stress by promoting Akt phosphorylation. This reveals a novel mechanism by which EGCG protects against IDD. It has been believed that activation of nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway stimulates the synthesis of antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione-peroxidase (GSH-Px), leading to enhancement of antioxidant defense system. Moreover, activated PI3K/Akt signaling can promote nuclear translocation of Nrf2 and subsequent upregulation of HO-1 expression under oxidative stress. Thus, it is likely that activation of Nrf2/HO-1 pathway by the PI3K/Akt signaling is, at least partially, responsible for EGCG-mediated attenuation of oxidative damage during IDD.
Mitochondrion dysfunction is a major cause of excessive reactive oxygen species (ROS) production, the hallmark of oxidative stress. ROS has been shown to induce NP and AF cell apoptosis through the mitochondria pathway. Noticeably, the PI3K/Akt signaling pathway can affect ROS-stimulated apoptosis in these cells. For example, administration of chlorogenic acid markedly decreased ROS production and inhibited apoptosis by activating the PI3K/Akt signaling in H2O2-treated rat NP cells. In human degenerative NP cells exposed to H2O2, EGCG promoted the phosphorylation of Akt, leading to decreased mitochondrial membrane depolarization and increased cellular survival. Taking these findings into account, activating this signaling cascade may be an important approach for alleviation of intradiscal oxidative damage by blocking the mitochondria apoptotic pathway.
Adaptation of hypoxic microenvironment
Since the disc is avascular, the main components within the disc, including water, aggrecan and fibrillar collagens, proportionally vary considerably depending on the location across the disc. Moreover, there is always a steep concentration gradient of oxygen across the disc, with pO2 falling to as low as 1 % in the center of the disc. Therefore, the IVD resides in a hypoxic microenvironment, which is essential for maintaining its normal physiological functions, including cellular metabolism and protein synthesis.
The IVD cells have developed some important mechanisms to ensure their survival in the hypoxic microenvironment of the disc. Hypoxia-inducible factor-1α (HIF-1α), an important transcription factor, is responsible for the induction of genes that facilitates adaptation and survival of cells and tissues under hypoxia condition. Risbud et al. detected HIF-1α expression in rat, human, and sheep NP cells in the presence of either hypoxia or normoxia, and found that these cells consistently expressed functionally active HIF-1α in the presence of hypoxia. Given the fact that activation of the PI3K/Akt signaling can upregulate HIF-1α expression under hypoxia in multiple cell types, this pathway may be also implicated in upregulation of HIF-1α expression induced by hypoxia in NP cells. On the other hand, Risbud et al. observed that under serum starvation condition, hypoxic contributed to attenuating apoptosis of rat NP cells. Moreover, cell survival in response to hypoxia was associated with activation of the PI3K/Akt/GSK3β signaling pathway. Thus, activated PI3K/Akt pathway can enhance the adaptation of NP cells to hypoxic microenvironment.
CONCLUSIONS AND FUTURE PERSPECTIVES
Although activated PI3K/Akt pathway has been shown to protect against disc degeneration through multiple mechanisms, there are a number of outstanding issues that need to be addressed. One of the most important aspects is the fact that no signaling pathway operates in isolation, which necessitates further investigation into how this pathway interacts with other signaling mediators. Establishment and application of chemically defined culture conditions would greatly promote such investigations and diminish non-associated signaling interference. The nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways have been frequently reported to be implicated in disc degeneration. Considering NF-κB and MAPK as downstream effectors of Akt, it is also important to clarify whether this pathway affects the development of IDD via regulation of NF-κB and MAPK. Hyperactivation of the PI3K/Akt pathway has been frequently reported in a wide variety of malignant tumors. Whether targeting this pathway in disc degeneration would lead to tumorigenesis is a considerable issue. Like MMPs, ADAMTSs are responsible for the degradation of Col II and aggrecan. It remains unclear whether this pathway inhibits ECM catabolism in the disc through downregulation of ADAMTS expression. In summary, more research into this pathway contribute to developing novel biological treatments for disc degeneration.
References 139
- 1.
Andersson GB. Epidemiological features of chronic low-back pain. Lancet. 1999;354:581-85.
Not in our library10.1016/s0140-6736(99)01312-4
- 2.
Lin CC, Li Q, Williams CM, Maher CG, Day RO, Hancock MJ, Latimer J, Mclachlan AJ, Jan S. The economic burden of guideline-recommended first line care for acute low back pain. Eur Spine J. 2016.
Not in our library10.1007/s00586-016-4781-0
- 3.
Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 2008;8:8-20.
Not in our library10.1016/j.spinee.2007.10.005
- 4.
Furlan AD, Yazdi F, Tsertsvadze A, Gross A, Van Tulder M, Santaguida L, Cherkin D, Gagnier J, Ammendolia C, Ansari MT, Ostermann T, Dryden T, Doucette S, et al. Complementary and alternative therapies for back pain II. Evid Rep Technol Assess (Full Rep). 2010;194:1-764.
Not in our library
- 5.
Millecamps M, Tajerian M, Naso L, Sage EH, Stone LS. Lumbar intervertebral disc degeneration associated with axial and radiating low back pain in ageing SPARC-null mice. Pain. 2012;153:1167-79.
Not in our library10.1016/j.pain.2012.01.027
- 6.
Battié MC, Videman T, Parent E. Lumbar disc degeneration: epidemiology and genetic influences. Spine. 2004;29:2679-90.
Not in our library10.1097/01.brs.0000146457.83240.eb
- 7.
Feng Y, Egan B, Wang J. Genetic Factors in Intervertebral Disc Degeneration. Genes Dis. 2016;3:178-85.
Not in our library10.1016/j.gendis.2016.04.005
- 8.
Hemanta D, Jiang XX, Feng ZZ, Chen ZX, Cao YW. Etiology for Degenerative Disc Disease. Chin Med Sci J. 2016;31:185-91.
Not in our library10.1016/s1001-9294(16)30049-9
- 9.
Vo NV, Hartman RA, Patil PR, Risbud MV, Kletsas D, Iatridis JC, Hoyland JA, Le Maitre CL, Sowa GA, Kang JD. Molecular mechanisms of biological aging in intervertebral discs. J Orthop Res. 2016;34:1289-306.
Not in our library10.1002/jor.23195
- 10.
Weber KT, Jacobsen TD, Maidhof R, Virojanapa J, Overby C, Bloom O, Quraishi S, Levine M, Chahine NO. Developments in intervertebral disc disease research: pathophysiology, mechanobiology, and therapeutics. Curr Rev Musculoskelet Med. 2015;8:18-31.
Not in our library10.1007/s12178-014-9253-8
- 11.
Kadow T, Sowa G, Vo N, Kang JD. Molecular basis of intervertebral disc degeneration and herniations: what are the important translational questions? Clin Orthop Relat Res. 2015;473:1903-12.
Not in our library10.1007/s11999-014-3774-8
- 12.
Le Maitre CL, Binch AL, Thorpe AA, Hughes SP. Degeneration of the intervertebral disc with new approaches for treating low back pain. J Neurosurg Sci. 2015;59:47-61.
Not in our library
- 13.
Noriega DC, Ardura F, Hernández-Ramajo R, Martín-Ferrero MA, Sánchez-Lite I, Toribio B, Alberca M, García V, Moraleda JM, Sánchez A, García-Sancho J. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: a randomized controlled trial. Transplantation. 2016;1.
Not in our library10.1097/tp.0000000000001484
- 14.
Pereira CL, Teixeira GQ, Ribeiro-Machado C, Caldeira J, Costa M, Figueiredo F, Fernandes R, Aguiar P, Grad S, Barbosa MA, Gonçalves RM. Mesenchymal Stem/Stromal Cells seeded on cartilaginous endplates promote Intervertebral Disc Regeneration through Extracellular Matrix Remodeling. Sci Rep. 2016;6:33836.
Not in our library10.1038/srep33836
- 15.
Elabd C, Centeno CJ, Schultz JR, Lutz G, Ichim T, Silva FJ. Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study. J Transl Med. 2016;14:253.
Not in our library10.1186/s12967-016-1015-5
- 16.
Vasiliadis ES, Pneumaticos SG, Evangelopoulos DS, Papavassiliou AG. Biologic treatment of mild and moderate intervertebral disc degeneration. Mol Med. 2014;20:400-09.
Not in our library10.2119/molmed.2014.00145
- 17.
Priyadarshani P, Li Y, Yao L. Advances in biological therapy for nucleus pulposus regeneration. Osteoarthritis and cartilage/OARS. Osteoarthritis Research Society. 2016;24:206-12.
Not in our library10.1016/j.joca.2015.08.014
- 18.
Le Maitre CL, Pockert A, Buttle DJ, Freemont AJ, Hoyland JA. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans. 2007;35:652-55.
Not in our library10.1042/bst0350652
- 19.
Boubriak OA, Watson N, Sivan SS, Stubbens N, Urban JP. Factors regulating viable cell density in the intervertebral disc: blood supply in relation to disc height. J Anat. 2013;222:341-48.
Not in our library10.1111/joa.12022
- 20.
Yang W, Yu XH, Wang C, He WS, Zhang SJ, Yan YG, Zhang J, Xiang YX, Wang WJ. Interleukin-1beta in intervertebral disk degeneration. Clin Chim Acta. 2015;450:262-72.
Not in our library10.1016/j.cca.2015.08.029
- 21.
Li T, Mo H, Chen W, Li L, Xiao Y, Zhang J, Li X, Lu Y. Role of the PI3K-Akt Signaling Pathway in the Pathogenesis of Polycystic Ovary Syndrome. Reprod Sci. 2017;24:646-55.
Not in our library10.1177/1933719116667606
- 22.
Zhang J, Yu XH, Yan YG, Wang C, Wang WJ. PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 2015;444:182-92.
Not in our library10.1016/j.cca.2014.12.041
- 23.
Jellusova J, Rickert RC. The PI3K pathway in B cell metabolism. Crit Rev Biochem Mol Biol. 2016;51:359-78.
Not in our library10.1080/10409238.2016.1215288
- 24.
Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, Padhye SB, Sarkar FH. Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem. 2013;13:1002-13.
Not in our library10.2174/18715206113139990078
- 25.
Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene. 2005;24:7493-501.
Not in our library10.1038/sj.onc.1209087
- 26.
- 27.
Rubashkin MG, Cassereau L, Bainer R, DuFort CC, Yui Y, Ou G, Paszek MJ, Davidson MW, Chen YY, Weaver VM. Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate. Cancer Res. 2014;74:4597-611.
Not in our library10.1158/0008-5472.can-13-3698
- 28.
- 29.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-101.
Not in our library10.1126/science.1106148
- 30.
Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, Wei W. PtdIns(3,4,5) P3-Dependent Activation of the mTORC2 Kinase Complex. Cancer Discov. 2015;5:1194-209.
Not in our library10.1158/2159-8290.cd-15-0460
- 31.
Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-57.
Not in our library10.1038/ncb839
- 32.
Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-45.
Not in our library10.1101/gad.1212704
- 33.
Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010;328:1172-76.
Not in our library10.1126/science.1187532
- 34.
Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, Li B. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 2011;71:835-45.
Not in our library10.1002/pros.21300
- 35.
Jin J, Jin L, Lim SW, Yang CW. Klotho Deficiency Aggravates Tacrolimus-Induced Renal Injury via the Phosphatidylinositol 3-Kinase-Akt-Forkhead Box Protein O Pathway. Am J Nephrol. 2016;43:357-65.
Not in our library10.1159/000446447
- 36.
- 37.
Zhao GX, Pan H, Ouyang DY, He XH. The critical molecular interconnections in regulating apoptosis and autophagy. Ann Med. 2015;47:305-15.
Not in our library10.3109/07853890.2015.1040831
- 38.
Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J. 2008;415:333-44.
Not in our library10.1042/bj20081056
- 39.
Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003;22:3113-22.
Not in our library10.1038/sj.onc.1206451
- 40.
Okumura N, Yoshida H, Kitagishi Y, Murakami M, Nishimura Y, Matsuda S. PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis. Adv Hematol. 2012;2012:843085.
Not in our library10.1155/2012/843085
Cited by papers we hold 1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.